Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6467512rdf:typepubmed:Citationlld:pubmed
pubmed-article:6467512lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:6467512lifeskim:mentionsumls-concept:C0596901lld:lifeskim
pubmed-article:6467512lifeskim:mentionsumls-concept:C0027022lld:lifeskim
pubmed-article:6467512lifeskim:mentionsumls-concept:C0836924lld:lifeskim
pubmed-article:6467512lifeskim:mentionsumls-concept:C0015684lld:lifeskim
pubmed-article:6467512lifeskim:mentionsumls-concept:C0678226lld:lifeskim
pubmed-article:6467512pubmed:issue1lld:pubmed
pubmed-article:6467512pubmed:dateCreated1984-10-3lld:pubmed
pubmed-article:6467512pubmed:abstractTextThe fatty acid composition of platelet membranes has been analysed in patients with thrombocytosis due to myeloproliferative disorders, who had not taken any drugs. A significant increase in palmitic and oleic acid, together with a decrease in stearic, linoleic and arachidonic acids was observed. The fatty acid pattern of platelet membranes was also analysed in patients during treatment with ASA (acetylsalicylic acid). ASA ingestion completely normalizes the platelet content of palmitic acid and partially that of stearic and arachidonic acid, whereas it has no effect on the level of linoleic acid and raises that of oleic acid. The altered pattern of fatty acids observed in patients may interfere with platelet function by decreasing membrane fluidity. Treatment of patients with ASA seems to act on platelet membranes by partially normalizing the fatty acid composition.lld:pubmed
pubmed-article:6467512pubmed:languageenglld:pubmed
pubmed-article:6467512pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6467512pubmed:citationSubsetIMlld:pubmed
pubmed-article:6467512pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6467512pubmed:statusMEDLINElld:pubmed
pubmed-article:6467512pubmed:monthJanlld:pubmed
pubmed-article:6467512pubmed:issn0263-6484lld:pubmed
pubmed-article:6467512pubmed:authorpubmed-author:BenattiUUlld:pubmed
pubmed-article:6467512pubmed:authorpubmed-author:MarescaMMlld:pubmed
pubmed-article:6467512pubmed:authorpubmed-author:LeonciniGGlld:pubmed
pubmed-article:6467512pubmed:authorpubmed-author:BalestreroFFlld:pubmed
pubmed-article:6467512pubmed:authorpubmed-author:ArmaniUUlld:pubmed
pubmed-article:6467512pubmed:authorpubmed-author:PianaAAlld:pubmed
pubmed-article:6467512pubmed:issnTypePrintlld:pubmed
pubmed-article:6467512pubmed:volume2lld:pubmed
pubmed-article:6467512pubmed:ownerNLMlld:pubmed
pubmed-article:6467512pubmed:authorsCompleteYlld:pubmed
pubmed-article:6467512pubmed:pagination23-5lld:pubmed
pubmed-article:6467512pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:meshHeadingpubmed-meshheading:6467512-...lld:pubmed
pubmed-article:6467512pubmed:year1984lld:pubmed
pubmed-article:6467512pubmed:articleTitlePlatelet membrane fatty acids in thrombocytosis due to myeloproliferative disorders.lld:pubmed
pubmed-article:6467512pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6467512pubmed:publicationTypeComparative Studylld:pubmed